ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

by Wei Nie, Zhi-Jie Wang, Kai Zhang, Bing Li, Yi-Ran Cai, Feng-Cai Wen, Ding Zhang, Yue-Zong Bai, Xue-Yan Zhang, Shu-Yuan Wang, Lei Cheng, Hua Zhong, Li Liu, Jie Wang, Bao-Hui Han
Published 2022-05-01

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

by Wu-tong Ju, Rong-hui Xia, Dong-wang Zhu, Sheng-jin Dou, Guo-pei Zhu, Min-jun Dong, Li-zhen Wang, Qi Sun, Tong-chao Zhao, Zhi-hang Zhou, Si-yuan Liang, Ying-ying Huang, Yong Tang, Si-cheng Wu, Jing Xia, Shi-qing Chen, Yue-zong Bai, Jiang Li, Qi Zhu, Lai-ping Zhong
Published 2022-09-01